Acumen Pharma Q1 net loss $28.8M; Phase 2 Alzheimer's trial fully enrolled, results late 2026

Acumen Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.48

Net loss $28.8M in Q1 2025 ($14.9M Q1 2024); loss from operations $30.4M vs $17.8M.
R&D expenses $25.3M (up 104% YoY) driven by ALTITUDE-AD Phase 2 clinical trial costs.
Cash, cash equivalents and marketable securities $197.9M, expected to fund operations into early 2027.
Phase 2 ALTITUDE-AD study of sabirnetug fully enrolled (542 participants); topline data readout late 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.